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Abstract. A new solid-phase enzyme-linked competitive binding assay 
for vitamin B12 (cyanocobalamin) is described. The assay is based on the 
competition between analyte B12 molecules and a glucose-6-phosphate 
dehydrogenase-vitamin B12 conjugate for a limited number of R-protein 
binding sites immobilized on sepharose particles. After appropriate 
incubation and washing steps, the enzyme activity bound to the solid- 
phase is inversely related to the concentration of B12 in the sample. 
Under optimized conditions, the method can detect B12 in the range of 
3 x 10-1~ x 10 -8 M (using 100 #1 sample) with high selectivity over 
other biological molecules. 
Key words: vitamin B12 (cyanocobalamin), competitive binding assays, 
enzyme-vitamin conjugates, vitamin tablet analyses. 
Enzyme-immunoassays (EIA) are attractive alternatives to classical radio- 
immunoassay procedures for the detection of biomolecules at trace levels. 
Modern heterogeneous EIA methods are often based on the competition 
between the analyte and enzyme-labeled analyte molecules for antibody 
binding sites immobilized on a solid phase [1, 2]. After appropriate sepa- 
ration and washing steps, the measured enzyme catalytic activity bound to 
the solid support is inversely proportional to the concentration of analyte in 
the sample. While selective antibodies have been the reagents most often 
used to devise such methods, we recently demonstrated the advantages of 
using immobilized natural binders [3--5] in place of antibodies, particularly 
in cases where the preparation of antibodies toward the analyte is difficult. 
We now report an extension of this new concept by describing a very simple 
solid-phase enzyme-linked method suitable for the direct determination of 
vitamin B12 (cyanocobalamin, CNCbl). 
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The two bioanalytical methods most often used to detect B12 include 
microbiological assays [6, 7] and radioassay competitive binding methods 
[7--10]. The microbiological method is very slow (1--2 days) and yields 
only semiquantitative values. The competitive binding technique involves 
the use of a 57Co-cobalamin in conjunction with various vitamin B12 
selective binders (R-protein, Intrinsic Factor, and TranscobalaminII) 
insolubilized on solid supports [7--13]. While extremely sensitive, the 
radioassay method is plagued by the need to use and dispose of radio- 
active material. 
Recently [14], we introduced a new homogeneous enzyme-linked assay 
for vitamin B~2 based on the inhibition of glucose-6-phosphate dehy- 
drogenase-vitamin B12 (G6PDH-Ba2) conjugates by soluble R-protein. This 
homogeneous method was quite rapid and selective; however, even under 
optimized conditions, the proposed assay could only detect B12 at levels 
>10 nM. In the assay described here, we report results obtained when 
using an immobilized form of R-protein in conjunction with similar 
G6PDH-Bu conjugates. By employing a heterogeneous assay protocol, the 
detection capabilities of the enzyme-linked competitive binding method are 
improved significantly (down to 0.3 nM). The final assay is selective for B~2 




Enzyme activities were measured with a Gilford (Oberlin, OH) Stasar III  Spectrophotometer 
equipped with a vacuum-operated sampling system and temperature-controlled cuvette. The 
cuvette chamber was maintained at 30 ~ C. The spectrophotometer was interfaced with a Syva 
CP-5000 EMIT Clinical Processor. 
Reagents 
Porcine R-protein (non-intrinsic factor), vitamin B12 , glucose-6-phosphate dehydrogenase 
(G6PDH) (from Leuconostoc mesenteroides), as well as all other biochemicals were obtained 
from Sigma Chemical Co. (St. Louis, MO). 
Substrate solutions (glucose-6-phosphate, fl-NAD +) were prepared in 0.050M 
Tris(hydroxymethyl)aminomethane-hydrochloric acid (Tris-HCl) buffer, pH 7.8, containing 
0.10 M NaC1 and 0.01% (w/v) NaN3 (assay buffer). Conjugates, standards, and binding 
protein solutions were prepared in the same buffer also containing 0.1% (w/v) gelatin 
(Tris-gel buffer). Gelatin was added to reduce non-specific adsorption of the enzyme-B12 
conjugate or analyte B12 molecules onto the walls of the test tubes and the solid-phase R- 
protein beads. The vitamin preparations and the infant formula analyzed were commercially 
available and their manufacturers and compositions are listed in Table 1. 
A standard stock solution of vitamin B12 was prepared by dissolving a given amount of 
cyanocobalamin in assay buffer. The concentration of this stock solution was determined 
spectrophotometrically using a molar extinction coefficient for CNCbl at 361nm, 
E361 = 28060 1 mo1-1 cm -1. Standards solutions of B12 in the range of 10-11--10 6 Mwere  
prepared by diluting this stock solution with Tris-gel buffer. 
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Table 1. Composition of analyzed samples 
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Content B complex a B complex b Folic acid c 




(rag/5 fl oz) 
Vitamin K 
Vitamin B1 50 
Vitamin B 2 50 
Vitamin B 6 50 
Vitamin B12 0.05 
Vitamin C 50 
Niacinamide 50 
Biotin 0.05 
Pantothenic acid 50 
Choline 50 
Inositol 50 
Para-amino benzoic acid 50 

























a Bio-genics, Woodland Hills, CA 
b The Kroger Co., Cincinnati, OH 
~ Makers of KAL, Inc., Woodland Hills, CA 
Similac, Ross Laboratories, Columbus, OH 
* Contains numerous inorganic salts 
Preparation of G6PDH-B12 Conjugate 
A G6PDH-B12 conjugate  conta in ing  approx imate ly  6.4 B12 molecules  per  
enzyme was synthesized f rom monoca rboxy l i c  acid derivatives o f  B12 using 
the p rocedu re  descr ibed in an earlier pape r  [14]. This conjugate  possessed  
83% of  its original  enzymat ic  activity fol lowing the con juga t ion  reaction.  
Preparation of R-Protein Solid-Phase Reagent 
R-prote in  sol id-phase  beads  were p repa red  by covalent ly a t taching 
0.485 mg of  R-pro te in  to 900 mg of  commerc ia l  C N B r  act ivated Sepharose  
4B  particles accord ing  to the  m e t h o d  suggested by the manufac tu re r  [15]. 
Briefly, the act ivated gel was swollen and  washed  in 1 m M  HC1 solut ion  (in 
order  to remove  dext ran  and lactose, which  are a d d e d  to the act ivated gel to 
preserve its activity unde r  freeze-drying).  The pro te in  to be coup led  
was dissolved in coupl ing  buffer  (0.1 M NaHCO3,  p H  8.3, 0.5 M NaC1) 
and  then  a d d e d  to the gel suspens ion  and incuba ted  for 2 h. Excess 
p ro te in  was washed  away and  the remain ing  active groups  in the 
beads  were b locked  using glycine. After the coupl ing  was comple t ed  
and  the remain ing  active groups  blocked,  the excess b locking reagent  
and  adsorbed  pro te in  were washed  away by al ternatively washing  the 
beads  with high and  low p H  buffer  solutions.  The sol id-phase  was 
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finally resuspended in a 1 : 5 suspension (ratio of beads to total volume of 
Tris-gel buffer) and stored at 4~ This suspension was further diluted 
(1:66) with Tris-gel buffer for use as a reagent in the heterogeneous 
competitive binding assay. 
The solid phase binding beads could be stored for at least three months 
without significant changes in their ability to bind G6PDH-B12 conjugates. 
However, attempts to regenerate (by washing with an alkaline glycine 
buffer, pH 12.9 [16]) the solid-phase after use in the B12 assays resulted in 
beads that retained only 30% of their initial conjugate binding capacity. 
Thus, fresh solid-phase reagent was always used for each B12 assay and to 
obtain calibration data. 
Heterogeneous Assays for Vitamin B12 
The assays were carried out in a single incubation (equilibrium) mode. This 
was accomplished by mixing 100#1 of the standard or sample solution with 
100 yl of a conjugate solution and 200 #1 of an R-protein suspension with 
400 r Tris-gel buffer. After an incubation period of 2.5 h, the beads were 
centrifuged and washed three times with assay buffer. One hundred r of 
each enzyme substrate, G6P (0.10 M) and fl-NAD + (0.063 M), and 800 j.tl of 
assay buffer were then added and the tubes were incubated again for 2 h. 
After this time, the beads were centrifuged and the absorbance of the super- 
natant was measured at 340 nm. 
Sample Preparations and Vitamin B12 Determinations 
Infant formula. Samples of the liquid infant formula were used as is or 
diluted 1 : 2 with Tris-gel buffer. 
Vitamin tablets. For the folic acid with B12 vitamin preparation, 12 tablets 
were ground and the amount equivalent to 3 tablets was weighed and mixed 
with deionized H20 in a 50 ml centrifuge tube. The solution was shaken, 
end to end, for 1 h at 4 ~ C. The suspension was then centrifuged four times 
at 2400 rpm for 10 rain intervals. The supernatant was transferred, after 
each centrifugation step, to a 100 ml volumetric flask. The volume was then 
completed up to 100 ml with deionized H20. Several dilutions of the super- 
natant were made with Tris-gel buffer. For the B-complex preparations 
(with and without Vitamin C), 10 tablets were ground together and the 
amount equivalent to one tablet was weighed and added to a 1000 ml volu- 
metric flask. The volume was completed to mark with deionized H20 and 
this solution was stirred for 24 h at 4 ~ C. From this sample solution, further 
dilutions in Tris-gel buffer were prepared. 
The resulting samples were stored at 4~ and protected from light. 
These samples were analyzed according to the heterogeneous assay 
protocol described above, along with the standards. The unknown concen- 
trations were estimated graphically from the calibration curve. Only the 
steep portion of the dose response curve was used for analytical purposes. 
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For the recovery study, a concentrated infant formula solution was 
spiked with 100 ~1, 500 r or 1500/.tl of a 3.5 • 10-7MB12 standard solution. 
These spiked solutions were then diluted 1 : 5 with Tris-gel buffer. The rest 
of the procedure was the same as for the analysis of the unspiked infant 
formula. 
Results and Discussion 
Since the binding interaction of G6PDH-B12 and R-protein in solution 
previously had been found to induce inhibition of enzymatic activity [14], 
we initially wanted to determine whether the immobilized form of R-protein 
would yield an analogous effect. To investigate this, varying amounts of the 
solid-phase R-protein reagent were incubated for 30 min with a given 
amount of G6PDH-B12 conjugate (1.25 x 10 -9 M), in the presence of the 
substrates G6P and fl-NAD +. After centrifugation, the absorbance of the 
supernatant was measured and compared to that obtained for the same 
experiment in the absence of solid-phase R-protein (full activity). While 
nearly 30% inhibition was observed in the presence of excess (i. e., 30 r 
absolute volume) solid-phase R-protein (compared to 65% for the same 
conjugate when soluble R-protein is employed [14]) insignificant effects 
(2--4% inhibition) were found when the amount of solid-phase R-protein 
equalled that normally employed in the solid-phase enzyme-linked compet- 
itive assay protocol (2--4/.tl; limiting reagent). Thus, we concluded that the 
inhibition induced by the immobilized R-protein would not cause problems 
when attempting to utilize G6PDH-Bn conjugates in devising a heteroge- 
neous competitive binding assay for Ba2. 
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Fig. 1. G6PDH-B12 conjugate (9.4x 10-1~ M) binding as a function of increasing immo- 
bilized R-protein solid-phase (volume refers to settled volume of R-protein beads). Data 
points are average of two determinations 
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In order to determine the capacity of the solid-phase R-protein for 
binding the G6PDH-B~2 conjugate (not the actual binding constant), varying 
amounts of the R-protein reagent were incubated with a fixed level of 
conjugate. After 3 h, the activity of conjugate bound to the solid phase was 
determined. Fig. 1 illustrates the results of such an experiment. At higher 
levels of R-protein beads, the amount of bound conjugate activity levels off 
to about 40% of that initially added to the reaction mixture. Given that at 
high levels of R-protein beads there is also some inhibition of the conjugate 
(see above discussion), we estimate that about 60% of the starting G6PDH- 
B12 conjugate can be bound by the immobilized R-protein. The remainder of 
the conjugate molecules probably cannot bind to the solid-phase due to 
steric factors (i. e., their covalently bound B~2 molecules are in regions inac- 
cessible for binding to the solid phase). Generally, for the heterogeneous 
competitive binding assays, we chose an amount of solid phase R-protein 
which fell on the steep portion of the binding curve (e.g. 1--3/,tl absolute 
bead volume) (see Fig. 1). 
The kinetics of the binding of G6PDH-B12 to immobilized R-protein was 
also examined (Fig. 2). We observed that binding of the conjugate to the 
solid phase continues to increase somewhat, even after a 3 h equilibration 
period. However, the rate of binding is significantly slowed after the first 
2 h and thus, in subsequent competitive binding assays, we chose a 2.5 h 
time period for all incubations between the conjugate, immobilized binder, 
and standards or samples. Interestingly, in related work [5], we observed 
that the overall kinetics of conjugate binding are enhanced when the solid- 
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Fig. 2. G6PDH-B12 conjugate (1.88 x 10-9/140 binding to R-protein beads (4.5 #l absolute 
bead volume) as a function of  increasing incubation time. Data points are average of two 
determinations 
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Fig. 3. Typical competitive binding dose-response curve toward B12 (M) using 1.9 x 10 -9 M 
G6PDH-B12 conjugate and 1.5 #1 absolute bead volume of solid-phase R-protein. Data 
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we purpose ly  p r epa red  our  sol id-phase  reagent  using high mass ratios of  
Sepharose  beads  to R-protein.  
Fig. 3 shows a typical  B12 dose- response  curve obta ined  using the 
var ious  reagents  in a compet i t ive  b ind ing  assay protocol .  The de tec t ion  
ranges,  s teepness  o f  the curves, and  detect ion limits vary depend ing  on the 
concent ra t ions  o f  reagents  used.  To obta in  op t imized  detec t ion  limits 
(Fig. 3; 3 x 10 -1~ M B12 in sample)  low levels of  conjugate  (1.90 x 10 -9 M) 
and  b inder  (1.5 yl absolute  vo lume)  were employed .  A l though  b o u n d  
enzyme activities cou ld  be mon i to r ed  using shor ter  incuba t ion  t imes,  we 
chose  a 2 h t ime pe r iod  to improve  the  precis ion of  the  m e t h o d  (i.e., longer  
react ion t imes allow for slight differences in the t ime be tween reagent  addi-  
Table 2. Results for the determination of B12 in 
various samples 
S ample Found a Claimed 
#g/tablet 
B complex with C 45 +2 50 
B complex 46 +8 50 
Folic acid with B12 4.9-4-0.3 5.0 
Infant formula 4.2_+ 0.4 nM 2.5 nM 
a Average of four determinations (+ std. dev.) 
for vitamin preparations and six determina- 
tions (+ std. dev.) for infant formula 
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tions, a situation which occurs when working with a large number of assay 
tubes). 
The precision, selectivity, and ultimate analytical utility of the proposed 
solid-phase assay was evaluated by determining the B12 content of various 
commercial vitamin and infant formula preparations (see Tables 1 and 2). 
Results obtained for the vitamin tablets were in good agreement with the 
manufacturer's claims. This agreement, even when B12 is the minor 
component, illustrates that the method offers high selectivity over other 
common vitamins. Results for the infant formula were substantially higher 
than the labeled values. However, according to the manufacturer, the 
difference between minimum (labeled) and actual determined values can be 
quite high to ensure an adequate shelf-life fo r the  product. Indeed, subse- 
quent analytical recovery studies using the protein-based infant formula 
preparation (Table 3) yielded satisfactory accuracy, suggesting that the 
method can be used for direct B12 measurements in rather complex samples. 
Attempts to use the existing assay for measurements of serum B12 levels 
were not undertaken since physiological concentrations of B12 fall at or 
below the detection limits of the new enzyme-linked method [7]. The 
detection limits obtainable in the enzyme-linked method appear to be 
restricted by the binding affinity of the immobilized R-protein toward the 
enzyme-labeled conjugate and analyte B12 molecules. Although previous 
workers have found that radioactive Ba2 binds to immobilized R-protein 
with high affinity, as suggested by low detection limits on competitive ra- 
dioassay [13, 17], using a Scatchard analysis method, we found that the 
G6PDH-Ba2 conjugate employed in this work bound to our R-protein solid- 
phase with an affinity constant of approximately 3.4 x 10 8 M -a [18]. This 
value is nearly 3 orders of magnitude lower than that reported (3 x 10 aa 
M -1) for the binding of radioactive Ba2 with a similar R-protein solid-phase 
[19]. Thus, steric effects owing to the bulkiness of the Ba2 conjugate and/or  
the specific spatial orientation of the immobilized R-protein may be 
contributing to this low value. Improved binding of the enzyme conjugate 
to the solid-phase, and consequently better competitive binding assay 
detection capabilities may be achieved by replacing R-protein with a 
different natural Ba2 binder. Indeed, preliminary studies using immobilizing 
intrinsic factor are now in progress [18]. However, since intrinsic factor is 
more selective in its binding (i.e., it can differentiate among the mono- 
Table 3. Results from recovery studies for the addi t ion of  
B12 to infant formula  
Sample  Vitamin B12 (nM) Recovery (%) 
A d d e d  Total  found a 
1 2.09 1.94 93 
2 3.33 3.18 96 
3 4.58 4.62 101 
a Average of  two determinat ions  
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carboxylic acid isomers of B12 [19, 20]), synthesis of new conjugates 
prepared with only the "e"-monocarboxylic acid derivative of B12 , rather 
than a mixture of monocarboxylic acids, will be required. 
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